Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing.
Title | Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Polyzos, S. A., & Goulas A. |
Journal | Med Hypotheses |
Pagination | 110379 |
Date Published | 2020 Nov 07 |
ISSN | 1532-2777 |
Abstract | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a disease of high prevalence without any approved treatment. Nonalcoholic steatohepatitis (NASH) is an advanced phenotype of the disease and the main focus of ongoing clinical trials. Denosumab, a human monoclonal antibody, which binds and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), is a licensed medication for postmenopausal, male and glucocorticoid-induced osteoporosis, as well as for metastatic bone disease associated with specific cancers. Hepatic RANKL upregulation has been shown in a transgenic mice model. |
DOI | 10.1016/j.mehy.2020.110379 |
Alternate Journal | Med Hypotheses |
PubMed ID | 33208241 |